NEW YORK, Feb. 18, 2022, a global leader in genomics and precision medicine, today announced it has partnered with The Renato Dulbecco Foundation to deliver more personalized therapies in rare diseases
Investegate announcements from Dante Labs, Dante Labs Partnering with The Renato Dulbecco Foundation to advance personalized medicines for cancer, COVID-19 and rare diseases
Celltrion set to win EC approval for biosimilar to Humira medicine
Posted : 2020-12-11 12:41
Updated : 2020-12-11 17:18
Celltrion scientists work on a Humira biosimilar medicine at the company s research center in Songdo, Incheon. / Courtesy of Celltrion
By Kim Hyun-bin
Celltrion received a sales approval recommendation from the European Medicine Agency (EMA) for its CT-P17 drug, Thursday local time.
The recommendation came from the EMA s Committee for Human Medical Products (CHMP).
CHMP is an organization within the EMA that conducts scientific evaluation of a new medicine and submits an approval recommendation. This is practically considered a sales approval.
CT-P17 is a biosimilar of Humira and used to treat a range of illnesses, including rheumatoid arthritis. It will become the first of the high-level Humira biosimilar drugs to be introduced in the European market.